卡泊芬净治疗恶性血液病化疗后中性粒细胞缺乏合并深部真菌感染的临床观察
|
摘要
目的分析卡泊芬净治疗恶性血液病化疗后中性粒细胞缺乏合并深部真菌感染的临床效果。方法选取2013年12月~2015年11月本院收治的69例恶性血液病化疗后中性粒细胞缺乏合并深部真菌感染患者,按照入院先后顺序,分为实验组(37例)与对照组(32例)。对照组给予两性霉素B治疗,实验组给予卡泊芬净治疗。比较两组患者的治疗效果。结果实验组的总有效率为86.5%,对照组为81.2%,组间差异无统计学意义(P>0.05)。实验组的总不良反应发生率为8.1%,明显低于对照组的21.8%,差异有统计学意义(P<0.05)。结论恶性血液病化疗后中性粒细胞缺乏合并深部真菌感染,早期接受卡泊芬净治疗,可取得满意效果,不良反应少,具有推广价值。
Objective To analyze the clinical effect of Caspofungin treating neutrophil deficiency combined with deep fungal infection after chemotherapy used for malignant hematologic disease.Methods 69 patients with neutrophil deficiency combined with deep fungal infection after chemotherapy used for malignant hematologic disease treated in our hospital from December 2013 to November 2015 were selected and they were divided into experimental group(37 cases)and control group(32 cases) according to order of admission.Control group was treated with Amphotericin B,while experimental group was treated with Caspofungin.The therapeutic effect between the two groups was compared.Results the total effective rate was 86.5% in experimental group and it was 81.2% in control group,and there was no significant difference between the two groups(P>0.05).The total incidence rate of adverse reaction of experimental group was 8.1%,which was significantly lower than that of the control group(21.8%),and the difference was statistically significant(P<0.05).Conclusion Caspofungin received in early stage treating neutrophil deficiency combined with deep fungal infection after chemotherapy used for malignant hematologic disease can obtain satisfactory effect,and adverse reaction is few,and it has the value of popularization.
Objective To analyze the clinical effect of Caspofungin treating neutrophil deficiency combined with deep fungal infection after chemotherapy used for malignant hematologic disease.Methods 69 patients with neutrophil deficiency combined with deep fungal infection after chemotherapy used for malignant hematologic disease treated in our hospital from December 2013 to November 2015 were selected and they were divided into experimental group(37 cases)and control group(32 cases) according to order of admission.Control group was treated with Amphotericin B,while experimental group was treated with Caspofungin.The therapeutic effect between the two groups was compared.Results the total effective rate was 86.5% in experimental group and it was 81.2% in control group,and there was no significant difference between the two groups(P>0.05).The total incidence rate of adverse reaction of experimental group was 8.1%,which was significantly lower than that of the control group(21.8%),and the difference was statistically significant(P<0.05).Conclusion Caspofungin received in early stage treating neutrophil deficiency combined with deep fungal infection after chemotherapy used for malignant hematologic disease can obtain satisfactory effect,and adverse reaction is few,and it has the value of popularization.
引文
[1]李波,曹原,司继刚,等.重组人粒细胞集落刺激因子对化疗后中性粒细胞缺乏的有效性和安全性研究[J].药学与临床研究,2014,22(6):545-547.
[2]张欣.伊曲康唑与两性霉素B治疗恶性血液病化疗后真菌感染的临床对照研究[J].湖北理工学院学报,2014,30(1):59-61.
[3]王羽,展新荣,张彦平,等.急性白血病化疗后粒细胞缺乏患者深部真菌感染临床分析[J].中华医院感染学杂志,2013,23(13):3116-3117,3120.
[4]何慧清,黎伟超,李卫华,等.恶性血液病化疗后中性粒细胞缺乏合并深部真菌感染的临床分析[J].中国医药导报,2012,9(7):167-168.
[5]韩曦瑶,刘立根,谢英华,等.卡泊芬净治疗恶性血液病合并侵袭性肺部真菌感染的临床疗效观察[J].临床内科杂志,2014,31(11):769-771.
[6]支芸,张琳敏,沈奕新,等.卡泊芬净联合伏立康唑治疗恶性血液病患者合并侵袭性真菌感染28例护理体会[J].中国医药导刊,2014,16(9):1251-1252.
[7]刘月.卡泊芬净联合伏立康唑治疗恶性血液病继发侵袭性真菌感染临床研究[J].中国药业,2016,25(9):31-33.
[8]胥亚芝.恶性血液病合并真菌感染患者应用卡泊芬净联合伏立康唑治疗的护理分析[J].北方药学,2015,12(9):182-182.
[9]付岭,张涛,刘金梅,等.恶性血液病合并侵袭性真菌感染患者临床分析[J].中国热带医学,2014,14(2):204-206.
[10]黄文荣,邵青,李红华.伏立康唑+卡泊芬净联合治疗血液病患者侵袭性肺部曲霉菌属感染[J].中华医院感染学杂志,2010,20(9):1310-1312.
[11]黄琰,吴隼,张媛,等.恶性血液病患者侵袭性肺部真菌感染的临床特点与治疗研究[J].中华医院感染学杂志,2016,26(7):1536-1538.
[12]罗洪强,傅佳萍,钟永根,等.两性霉素B与卡泊芬净及伊曲康唑治疗恶性血液病患者侵入性真菌感染疗效比较[J].中华医院感染学杂志,2013,23(22):5530-5532.
[13]刘明娟,黄文荣,于力,等.恶性血液病患者中侵袭性真菌病的二级预防[J].中国实验血液学杂志,2015,23(2):596-600.
[14]王强.卡泊芬净治疗白色念珠菌血症的疗效观察[J].当代医学,2016,22(1):143-144.
[15]吴隼,字友梅,黄琰,等.恶性血液病患者侵袭性肺曲霉菌感染的治疗分析[J].中华医院感染学杂志,2014,24(16):3990-3992.
[16]曹永兵,张磊,王彦,等.伏立康唑及其临床应用[J].中国新药与临床杂志,2005,24(4):330-332.
[2]张欣.伊曲康唑与两性霉素B治疗恶性血液病化疗后真菌感染的临床对照研究[J].湖北理工学院学报,2014,30(1):59-61.
[3]王羽,展新荣,张彦平,等.急性白血病化疗后粒细胞缺乏患者深部真菌感染临床分析[J].中华医院感染学杂志,2013,23(13):3116-3117,3120.
[4]何慧清,黎伟超,李卫华,等.恶性血液病化疗后中性粒细胞缺乏合并深部真菌感染的临床分析[J].中国医药导报,2012,9(7):167-168.
[5]韩曦瑶,刘立根,谢英华,等.卡泊芬净治疗恶性血液病合并侵袭性肺部真菌感染的临床疗效观察[J].临床内科杂志,2014,31(11):769-771.
[6]支芸,张琳敏,沈奕新,等.卡泊芬净联合伏立康唑治疗恶性血液病患者合并侵袭性真菌感染28例护理体会[J].中国医药导刊,2014,16(9):1251-1252.
[7]刘月.卡泊芬净联合伏立康唑治疗恶性血液病继发侵袭性真菌感染临床研究[J].中国药业,2016,25(9):31-33.
[8]胥亚芝.恶性血液病合并真菌感染患者应用卡泊芬净联合伏立康唑治疗的护理分析[J].北方药学,2015,12(9):182-182.
[9]付岭,张涛,刘金梅,等.恶性血液病合并侵袭性真菌感染患者临床分析[J].中国热带医学,2014,14(2):204-206.
[10]黄文荣,邵青,李红华.伏立康唑+卡泊芬净联合治疗血液病患者侵袭性肺部曲霉菌属感染[J].中华医院感染学杂志,2010,20(9):1310-1312.
[11]黄琰,吴隼,张媛,等.恶性血液病患者侵袭性肺部真菌感染的临床特点与治疗研究[J].中华医院感染学杂志,2016,26(7):1536-1538.
[12]罗洪强,傅佳萍,钟永根,等.两性霉素B与卡泊芬净及伊曲康唑治疗恶性血液病患者侵入性真菌感染疗效比较[J].中华医院感染学杂志,2013,23(22):5530-5532.
[13]刘明娟,黄文荣,于力,等.恶性血液病患者中侵袭性真菌病的二级预防[J].中国实验血液学杂志,2015,23(2):596-600.
[14]王强.卡泊芬净治疗白色念珠菌血症的疗效观察[J].当代医学,2016,22(1):143-144.
[15]吴隼,字友梅,黄琰,等.恶性血液病患者侵袭性肺曲霉菌感染的治疗分析[J].中华医院感染学杂志,2014,24(16):3990-3992.
[16]曹永兵,张磊,王彦,等.伏立康唑及其临床应用[J].中国新药与临床杂志,2005,24(4):330-332.